IMM-1104 is under clinical development by Immuneering and currently in Phase II for Solid Tumor. According to GlobalData, Phase II drugs for Solid Tumor have a 10% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how IMM-1104’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

IMM-1104 overview

IMM-1104 (IMM-1611441) is under development for the treatment of solid tumor, pancreatic ductal adenocarcinoma, non-small cell lung cancer, metastatic colorectal cancer and NRAS mutant metastatic melanoma. It is administered through oral route. The drug candidate acts by targeting mitogen activated protein kinase (MEK) and kinase suppressor of RAS (KSR). It is developed based on Immuneering artificial intelligence (AI) enabled disease cancelling technology (DCT).

Immuneering overview

Immuneering is a biopharmaceutical company. It focuses on discovery and development of medicines to treat cancer and neurological diseases. The company is investigating IMM-1-104, a dual inhibitor of mitogen-activated protein kinase (MEK) to restrain the pathway that reduces the growth of tumors; and MEK-io IMM-6-415 program against cold solid tumors. It is also developing drugs to treat Alzheimer’s and other neurological disorders. Immuneering utilizes its disease cancelling platform technology which employs human gene expression data to design and develop medicines that alter disease signals covering various genes to produce drug candidates. It offers drug discovery services by leveraging artificial intelligence. The company provides bioinformatics and computational biology services to pharmaceutical and biotechnology companies. It operates with additional offices in New York and California, the US. Immuneering is headquartered in Boston, Massachusetts, the US.

For a complete picture of IMM-1104’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.